ITP Outcome Criteria: Standardized definitions for CR and R. A "Response" suggests the patient is effectively protected from spontaneous severe hemorrhage.
Guidelines & Evidence
Clinical Details
Section 1
When to Use
When to Use
Defining response to therapy (Steroids, IVIG, TPO-agonists, Rituximab) in patients with ITP.
Monitoring long-term durable response in chronic ITP.
Standardizing clinical trial primary and secondary endpoints.
Timing of Assessment
Initial response is typically assessed at 1 week (Steroids/IVIG). Sustained response should be assessed after cessation of therapy or during maintenance.
Section 2
Formula & Logic
Response Categories
Category
Platelet Threshold
Bleeding Status
Complete Response (CR)
≥ 100 × 10⁹/L
Absence of bleeding
Response (R)
≥ 30 × 10⁹/L AND 2-fold increase
Absence of bleeding
No Response (NR)
< 30 × 10⁹/L OR < 2-fold increase
Any bleeding
Loss of Response
Platelets < 30 × 10⁹/L
Less than 2-fold increase from baseline
Presence of bleeding symptoms
Section 3
Pearls/Pitfalls
Why 100k for CR?
While the normal range is 150-450k, a value of 100k in ITP represents a robust recovery that is highly unlikely to carry any spontaneous bleeding risk and marks a distinct immunological improvement.
The 'R' Safety Zone
The 30k threshold for "Response" is arguably the most important clinical marker, as spontaneous severe hemorrhage (especially CNS) is exceedingly rare once platelets exceed 30k.
Section 4
Evidence Appraisal
Primary Consensus
Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group.
Rodeghiero F et al. • Blood. 2009;113(11):2386-93.